STAT5 inhibitors are under development for hematologic cancers, yet our findings suggest that indiscriminate inhibition of STAT5 activity may inadvertently suppress STAT5B’s tumor-suppressive functions in solid tumors. This evidence concerns the gene STAT5B and hematopoietic and lymphoid cell neoplasm.